Citi initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $95 price target Healthcare policy remains a key biopharma sector ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Apogee Therapeutics (NasdaqGM:APGE) with a Buy ...

Shares of Apogee Therapeutics advanced after sharing positive interim results that push forward more trials of inflammatory and immunology treatments. The stock rose 6% to $33.37 on Monday. Shares ...

On Monday, Apogee Therapeutics, Inc. (NASDAQ:APGE) released interim Phase 1 results from its first-in-human trial of APG990. APG990 interim Phase 1 pharmacokinetic (PK) data showed a half-life of ...

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A ...